A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)

Hematological Oncology - United Kingdom
doi 10.1002/hon.137_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Safety and Early Data From a Phase Ii Trial of Pembrolizumab (Pem) and Entinostat (Ent) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (Hl) and Follicular Lymphoma (Fl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology
Hematology
2018English

Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy